Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$161.97 USD

161.97
575,208

+1.87 (1.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 6% (16 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Shaun Pruitt headshot

3 Top-Rated Stocks to Buy After Comfortably Surpassing Earnings Expectations

Investors are always looking for stocks of companies that illustrate business operations are stronger than anticipated and here are three to consider.

Debanjana Dey headshot

4 Stocks to Watch in a Resilient Outpatient Home Health Industry

The rising dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DVA, EHC, OPCH and ADUS are well-poised to gain.

DaVita Inc. (DVA) Soars to 52-Week High, Time to Cash Out?

DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

DaVita (DVA) Q4 Earnings & Revenues Top Estimates, Margins Up

DaVita's (DVA) robust segmental revenues drive its fourth-quarter performance.

DaVita HealthCare (DVA) Q4 Earnings and Revenues Top Estimates

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 22.22% and 4.82%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 Device

ResMed's (RMD) new AirCurve11 series incorporates myAir and AirView digital health apps to provide maximum comfort and support during therapy.

Here's Why You Should Retain Charles River (CRL) Stock Now

Charles River's (CRL) share price is likely to grow, backed by the strength of the RMS segment.

Quest Diagnostics (DGX) Debuts PFAS Blood Test Offering

Quest Diagnostics (DGX) introduces the first consumer-initiated blood test with physician consult on questhealth.com.

Shaun Pruitt headshot

Time to Buy These High Growth Stocks as Earnings Approach

This week's earnings lineup will be highlighted by several growth stocks with none standing out more than Airbnb (ABNB) and DaVita (DVA).

Here's Why You Should Add HealthEquity (HQY) to Your Portfolio

HealthEquity's (HQY) strength in HSA raises optimism about the stock.

Indrajit Bandyopadhyay headshot

Medical Device Stocks' Earnings Due on Feb 13: ECL, DVA & QDEL

Medical Device companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how ECL, DVA and QDEL fare this time.

DaVita (DVA) to Report Q4 Earnings: What's in the Offing?

Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the fourth quarter.

Here's Why You Should Invest in Boston Scientific (BSX) Now

Investors are optimistic about Boston Scientific (BSX) on strength across the target market and upbeat guidance.

IDEXX's (IDXX) Global Growth Continues, Currency Woes Persist

A key element of IDEXX's (IDXX) customer engagement strategy is the expansion of its commercial footprint in a disciplined approach.

Insulet's (PODD) Omnipod 5 Gets CE Mark for Added Compatibility

Insulet's (PODD) tubeless automated insulin delivery system's CE mark approval with multiple CGM sensor brands is likely to serve a wider patient pool.

Is Ardelyx (ARDX) Stock Outpacing Its Medical Peers This Year?

Here is how Ardelyx (ARDX) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

Hologic (HOLX) Introduces Genius Digital Diagnostics System

Hologic's (HOLX) Genius Digital Diagnostics System will assist laboratories and healthcare providers with the information needed to make more timely and successful treatment decisions for patients.

Three Reasons to Retain BD (BDX) Stock in Your Portfolio

BD's (BDX) slew of product launches raises optimism about the stock.

Edwards Lifesciences (EW) Wins FDA Nod for the EVOQUE System

Edwards Lifesciences' (EW) EVOQUE valve replacement system becomes the first transcatheter therapy to earn FDA approval for a tricuspid valve.

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

Strength of the base business bodes well for Quest Diagnostics (DGX).

Modular Medical (MODD) Pairing Technology Issued New U.S. Patent

Modular Medical's (MODD) latest U.S. patent is likely to protect the company's technology addressing pairing and allow clinicians to easily upload and review patients' data.

Boston Scientific's (BSX) FARAPULSE PFA System Gets FDA Nod

Boston Scientific (BSX) secures FDA approval for the FARAPULSE PFA system.

Trinity Biotech (TRIB) to Grow in Wearable Biosensor With Buyout

Trinity Biotech's (TRIB) focus on CGM as an initial step, utilizing a device with regulatory approval, provides a de-risked entry point in the wearable biosensor technology space.

Insulet (PODD) Gains From Product Innovation, Global Expansion

Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.

The Zacks Analyst Blog Highlights Arista Networks, Chipotle Mexican Grill, Netflix, DaVita and Royal Caribbean Cruises

Arista Networks, Chipotle Mexican Grill, Netflix, DaVita and Royal Caribbean Cruises are part of the Zacks top Analyst Blog.